Clinical Trials
8 trialsNCT00142454 2022-10-10
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT04072900 2020-04-28
A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma
Xiangya Hospital of Central South University
Phase 1 Unknown
NCT00118313 2020-03-27
Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
University of Virginia
Phase 1 Completed
NCT01264731 2016-12-16
MEL53
University of Virginia
Phase 1 Completed
NCT00453050 2015-05-06
Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin
National Cancer Institute (NCI)
Phase 1 Completed
NCT00828568 2014-01-28
Bioequivalence Study of Two Imiquimod Cream 5%
Sun Pharmaceutical Industries, Inc.
Phase 1 Completed
NCT01788007 2014-01-22
Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
Sun Pharmaceutical Industries, Inc.
Phase 1 Completed
NCT00079300 2013-04-26
Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed